No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients (Q59354752)
Jump to navigation
Jump to search
scientific article published on 09 August 2018
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients |
scientific article published on 09 August 2018 |
Statements
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients (English)
K Rajender Reddy
Christoph Sarrazin
Curtis L Cooper
Michael P Manns
Stuart K Roberts
Hadas Dvory-Sobol
Evguenia Svarovskia
Ross Martin
Gregory Camus
Brian P Doehle
Luisa M Stamm
Robert H Hyland
Diana M Brainard
Hongmei Mo
Stuart C Gordon
Marc Bourliere
Stefan Zeuzem